(Q38228516)

31 August 2017

Management of refractory OAB in the non-neurogenic patient (English)

1 reference

31 August 2017

1

1 reference

PubMed ID

25015301

31 August 2017

language of work or name

1 reference

1 September 2014

1 reference

31 August 2017

Current urology reports

1 reference

31 August 2017

15

1 reference

31 August 2017

9

1 reference

31 August 2017

438

1 reference

https://scigraph.springernature.com/pub.10.1007/s11934-014-0438-x

31 August 2017

0 references

cites work

Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Defining response and non-response to treatment in patients with overactive bladder: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

The medical management of refractory overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Global prevalence and economic burden of urgency urinary incontinence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Clinical and urodynamic differences among women with overactive bladder according to the presence of detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

A candidate serum biomarker for bladder pain syndrome/interstitial cystitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Double anticholinergic therapy for refractory overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Triple therapy in refractory detrusor overactivity: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Gabapentin: a novel drug as add-on therapy in cases of refractory overactive bladder in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Feasibility of Controlled Micturition through Electric Stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

PERCUTANEOUS AFFERENT NEUROMODULATION FOR THE REFRACTORY OVERACTIVE BLADDER: RESULTS OF A MULTICENTER STUDY

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Validation of a sham for percutaneous tibial nerve stimulation (PTNS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Transcutaneous electrical nerve stimulation: an effective treatment for refractory non-neurogenic overactive bladder syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Diagnosis and treatment of the overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Augmentation enterocystoplasty in overactive bladder: is there still a role?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

21 January 2018

Augmentation cystoplasty

1 reference

https://api.crossref.org/works/10.1007%2FS11934-014-0438-X

Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group

21 January 2018

1 reference

12 December 2020

Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics

1 reference

12 December 2020

Electrical stimulation in the clinical management of the neurogenic bladder

1 reference

12 December 2020

Economic burden of urgency urinary incontinence in the United States: a systematic review

1 reference

12 December 2020

Urinary prostaglandin E₂ was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome

1 reference

12 December 2020

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

1 reference

12 December 2020

Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results

1 reference

12 December 2020

Botulinum toxin A submucosal injection for refractory non-neurogenic overactive bladder: early outcomes

1 reference

12 December 2020

Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial

1 reference

12 December 2020

Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.

1 reference

12 December 2020

Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder

1 reference

12 December 2020

Functional pattern of sacral root stimulation in dogs. II. Urethral closure

1 reference

12 December 2020

Functional pattern of sacral root stimulation in dogs. I. Micturition.

1 reference

12 December 2020

Transcutaneous posterior tibial nerve stimulation: evaluation of a therapeutic option in the management of anticholinergic refractory overactive bladder.

1 reference

12 December 2020

10.1007/S11934-014-0438-X

Identifiers

DOI

1 reference

PubMed ID

25015301

Dimensions Publication ID

31 August 2017

0 references

1 reference

PubMed ID

25015301